NASDAQ:VRAY

ViewRay (VRAY) Stock Forecast, Price & News

$0.55

-0.03 (-5.22%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.53
▼
$0.58
50-Day Range: $0.53
▼
$3.28
52-Week Range: $0.51
▼
$4.96

Volume: 1.40 million shs
Average Volume: 2.07 million shs
Market Capitalization: $99.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.18

ViewRay MarketRank™ Forecast

Analyst Rating: Hold
2.14 Rating Score
Upside/Downside: 483.1% Upside
$3.18 Price Target
Short Interest: Healthy
4.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.41
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.58) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

158th out of 987 stocks

Electromedical Equipment Industry

4th out of 22 stocks

4.1

Analyst's Opinion

Consensus Rating
ViewRay has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.18, ViewRay has a forecasted upside of 483.1% from its current price of $0.55.
Amount of Analyst Coverage
ViewRay has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.01% of the float of ViewRay has been sold short.
Short Interest Ratio / Days to Cover
ViewRay has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ViewRay has recently increased by 0.69%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ViewRay does not currently pay a dividend.
Dividend Growth
ViewRay does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ViewRay has received a 77.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for ViewRay is -0.85.

1.3

News and Social Media Coverage

News Sentiment
ViewRay has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ViewRay this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for VRAY on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ViewRay to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ViewRay insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.50% of the stock of ViewRay is held by insiders.
Percentage Held by Institutions
84.40% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ViewRay are expected to grow in the coming year, from ($0.58) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ViewRay is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ViewRay is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ViewRay has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

May 26, 2023 | fool.com

ViewRay (NASDAQ: VRAY)

May 25, 2023 | markets.businessinsider.com

Viewray (VRAY) Receives a Hold from Stifel Nicolaus

June 9, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 20, 2023 | americanbankingnews.com

ViewRay (NASDAQ:VRAY) Research Coverage Started at StockNews.com

May 17, 2023 | americanbankingnews.com

ViewRay, Inc. (NASDAQ:VRAY) Receives $2.54 Average PT from Brokerages

May 16, 2023 | finance.yahoo.com

Do You Believe in the Growth Prospects of ViewRay (VRAY)?

May 16, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for ViewRay, Inc. Decreased by B. Riley (NASDAQ:VRAY)

May 14, 2023 | americanbankingnews.com

Stifel Nicolaus Lowers ViewRay (NASDAQ:VRAY) Price Target to $1.00

June 9, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 14, 2023 | americanbankingnews.com

ViewRay, Inc. (NASDAQ:VRAY) Short Interest Down 30.1% in April

May 13, 2023 | msn.com

Morgan Stanley Maintains ViewRay (VRAY) Equal-Weight Recommendation

May 12, 2023 | finance.yahoo.com

Need To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023

May 12, 2023 | finance.yahoo.com

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

May 11, 2023 | finanznachrichten.de

ViewRay, Inc.: ViewRay Announces First Quarter 2023 Results

May 11, 2023 | markets.businessinsider.com

B.Riley Financial downgrades Viewray (VRAY) to a Hold

May 11, 2023 | msn.com

B. Riley Securities Downgrades ViewRay (VRAY)

May 11, 2023 | msn.com

ViewRay hits 52-week low after pulling guidance

May 11, 2023 | americanbankingnews.com

ViewRay (NASDAQ:VRAY) Downgraded by B. Riley

May 11, 2023 | markets.businessinsider.com

BTIG Remains a Hold on Viewray (VRAY)

May 10, 2023 | finance.yahoo.com

ViewRay Announces First Quarter 2023 Results

May 9, 2023 | finance.yahoo.com

ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

April 27, 2023 | americanbankingnews.com

ViewRay (NASDAQ:VRAY) PT Lowered to $2.00 at Piper Sandler

April 24, 2023 | americanbankingnews.com

ViewRay, Inc. (NASDAQ:VRAY) Given Average Rating of "Hold" by Brokerages

April 19, 2023 | americanbankingnews.com

ViewRay, Inc. to Post Q3 2023 Earnings of ($0.14) Per Share, Jefferies Financial Group Forecasts (NASDAQ:VRAY)

April 18, 2023 | msn.com

Jefferies Downgrades Viewray (VRAY)

April 17, 2023 | markets.businessinsider.com

Jefferies downgrades Viewray (VRAY) to a Hold

April 17, 2023 | finance.yahoo.com

It's Down 63% But ViewRay, Inc. (NASDAQ:VRAY) Could Be Riskier Than It Looks

See More Headlines

VRAY Price History

30 days | 90 days | 365 days | Advanced Chart

VRAY Company Calendar

Last Earnings: 5/10/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VRAY
CUSIP: N/A
CIK: 1597313
Web: www.viewray.com
Phone: (440) 703-3210
Fax: 800-417-3459
Employees: 267
Year Founded: 2004

Price Target and Rating

Average Stock Price Forecast: $3.18
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +483.1%
Consensus Rating: Hold
Rating Score (0-4): 2.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-107,330,000.00
Net Margins: -104.30%
Pretax Margin: -104.30%
Return on Equity: -120.48%
Return on Assets: -42.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $102.21 million
Price / Sales: 0.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 183,400,000
Free Float: 178,817,000
Market Cap: $99.97 million
Optionable: Optionable
Beta: 0.93

Social Links

Key Executives

Scott William Drake
President, Chief Executive Officer & Director

Drew Hill
Senior Vice President-Operations & Development

William Patrick Burke
Chief Financial Officer & Executive Vice President

James F. Dempsey
Chief Scientific Officer

Martin Fuss
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings or view top-rated stocks.
What is ViewRay's stock price forecast for 2023?: 7 brokers have issued 1-year target prices for ViewRay's shares. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they predict the company's share price to reach $3.18 in the next twelve months. This suggests a possible upside of 483.1% from the stock's current price.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.
How have VRAY shares performed in 2023?: ViewRay's stock was trading at $4.48 at the start of the year. Since then, VRAY shares have decreased by 87.8% and is now trading at $0.5451.
View the best growth stocks for 2023 here.
When is ViewRay's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our VRAY earnings forecast.
How were ViewRay's earnings last quarter?: ViewRay, Inc. (NASDAQ:VRAY) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The company had revenue of $22.53 million for the quarter, compared to analysts' expectations of $22.64 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%.
What ETFs hold ViewRay's stock?: ETFs with the largest weight of ViewRay (NASDAQ:VRAY) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI).
What guidance has ViewRay issued on next quarter's earnings?: ViewRay issued an update on its FY 2023 earnings guidance on Tuesday, April, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $102.21 million-$117.54 million, compared to the consensus revenue estimate of $136.37 million.
What is Scott Drake's approval rating as ViewRay's CEO?: 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).
When did ViewRay IPO?: (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
What is ViewRay's stock symbol?: ViewRay trades on the NASDAQ under the ticker symbol "VRAY."
Who are ViewRay's major shareholders?: ViewRay's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (8.44%), Fosun International Ltd (6.60%), BlackRock Inc. (5.81%), Neuberger Berman Group LLC (5.63%), FMR LLC (2.90%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends.
How do I buy shares of ViewRay?: Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ViewRay's stock price today?: One share of VRAY stock can currently be purchased for approximately $0.55.
How much money does ViewRay make?: ViewRay (NASDAQ:VRAY) has a market capitalization of $99.97 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.
How many employees does ViewRay have?: The company employs 267 workers across the globe.
Does ViewRay have any subsidiaries?: The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
How can I contact ViewRay?: ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial